Table of Content

1. Service Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Prostate Cancer Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
5.2.1.1. Hormonal Therapy
5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
5.2.1.1.3. Anti-Androgen
5.2.1.2. Chemotherapy
5.2.1.2.1. Taxotere
5.2.1.2.2. Jevtana
5.2.1.3. Immunotherapy
5.2.1.3.1. Provenge
5.2.1.4. Target Therapy
5.2.1.4.1. Xofigo
5.2.1.5. Others
5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
5.3.1. By Treatment
5.3.2. By End User
6. North America Prostate Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
6.2.1.1. Hormonal Therapy
6.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
6.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
6.2.1.1.3. Anti-Androgen
6.2.1.2. Chemotherapy
6.2.1.2.1. Taxotere
6.2.1.2.2. Jevtana
6.2.1.3. Immunotherapy
6.2.1.3.1. Provenge
6.2.1.4. Target Therapy
6.2.1.4.1. Xofigo
6.2.1.5. Others
6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Prostate Cancer Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By End User
6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By End User
6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By End User
7. Europe Prostate Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
7.2.1.1. Hormonal Therapy
7.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
7.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
7.2.1.1.3. Anti-Androgen
7.2.1.2. Chemotherapy
7.2.1.2.1. Taxotere
7.2.1.2.2. Jevtana
7.2.1.3. Immunotherapy
7.2.1.3.1. Provenge
7.2.1.4. Target Therapy
7.2.1.4.1. Xofigo
7.2.1.5. Others
7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Prostate Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By End User
7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By End User
7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By End User
7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By End User
7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By End User
8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
8.2.1.1. Hormonal Therapy
8.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
8.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
8.2.1.1.3. Anti-Androgen
8.2.1.2. Chemotherapy
8.2.1.2.1. Taxotere
8.2.1.2.2. Jevtana
8.2.1.3. Immunotherapy
8.2.1.3.1. Provenge
8.2.1.4. Target Therapy
8.2.1.4.1. Xofigo
8.2.1.5. Others
8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Prostate Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By End User
8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By End User
8.3.3. India Prostate Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By End User
8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By End User
8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By End User
9. South America Prostate Cancer Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
9.2.1.1. Hormonal Therapy
9.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
9.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
9.2.1.1.3. Anti-Androgen
9.2.1.2. Chemotherapy
9.2.1.2.1. Taxotere
9.2.1.2.2. Jevtana
9.2.1.3. Immunotherapy
9.2.1.3.1. Provenge
9.2.1.4. Target Therapy
9.2.1.4.1. Xofigo
9.2.1.5. Others
9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By End User
9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By End User
9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By End User
10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
10.2.1.1. Hormonal Therapy
10.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
10.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
10.2.1.1.3. Anti-Androgen
10.2.1.2. Chemotherapy
10.2.1.2.1. Taxotere
10.2.1.2.2. Jevtana
10.2.1.3. Immunotherapy
10.2.1.3.1. Provenge
10.2.1.4. Target Therapy
10.2.1.4.1. Xofigo
10.2.1.5. Others
10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By End User
10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By End User
10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By End User
10.3.4. Turkey Prostate Cancer Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Treatment
10.3.4.2.2. By End User
10.3.5. Egypt Prostate Cancer Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Treatment
10.3.5.2.2. By End User
11. Market Dynamics
11.1. Drivers
11.1.1. Increasing Prevalence of Prostate Cancer.
11.1.2. Adoption of Novel Screening and Diagnostic Technologies
11.1.3. Surge in Research and Development
11.2. Challenges
11.2.1. High Cost of Cancer Treatment
11.2.2. Side Effects of Hormonal Treatment
12. Market Trends & Developments
12.1. Product Launches
12.2. Mergers & Acquisitions
12.3. Technological Advancements
13. Clinical Trial Analysis
14. Global Prostate Cancer Therapeutics Market: SWOT Analysis
15. Competitive Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (In Case of Listed Companies)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. Johnson & Johnson Services, Inc.
15.6.2. Astellas Pharma Inc.
15.6.3. Eli Lilly and Company
15.6.4. Sanofi S.A.
15.6.5. Ipsen Pharma
15.6.6. Bayer AG
15.6.7. AstraZeneca Plc
15.6.8. Valeant Pharmaceuticals International, Inc.
15.6.9. Merck & Co., Inc.
15.6.10. Pfizer Inc.
16. Strategic Recommendations